Immunotherapy of cancer through targeting of the p53 tumor antigen

Sander Zwaveling; Sjoerd H Van der Burg; Anand G Menon; Cornelis J M Melief; Rienk Offringa

Immunotherapy of cancer through targeting of the p53 tumor antigen

Arch Immunol Ther Exp (Warsz). 2002;50(5):297-305.

Authors

Sander Zwaveling¹, Sjoerd H Van der Burg, Anand G Menon, Cornelis J M Melief, Rienk Offringa

Affiliation

¹ Leiden University Medical Center, Department of Immunohematology and Blood Transfusion, Tumor Immunology Group, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.

PMID: 12455863

Abstract

The expression of the p53 tumor suppressor protein is frequently increased in a great variety of human cancers, making this antigen an attractive candidate for targeting therapeutic T cell immunity. However, potential complications as a result of immunological tolerance or autoimmune pathology must be taken into account when exploiting this ubiquitously expressed auto-antigen for the immunotherapy of cancer.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antigen Presentation
Antigens, Neoplasm / metabolism*
Autoimmunity
Colorectal Neoplasms / immunology
Colorectal Neoplasms / metabolism
Colorectal Neoplasms / therapy
Humans
Immune Tolerance
Immunotherapy / methods*
Neoplasms / immunology*
Neoplasms / metabolism
Neoplasms / therapy*
Nuclear Proteins*
Proto-Oncogene Proteins / metabolism
Proto-Oncogene Proteins c-mdm2
T-Lymphocytes, Helper-Inducer / immunology
Tumor Suppressor Protein p53 / immunology*

Substances

Antigens, Neoplasm
Nuclear Proteins
Proto-Oncogene Proteins
Tumor Suppressor Protein p53
MDM2 protein, human
Proto-Oncogene Proteins c-mdm2